Skip to main
LCTX

LCTX Stock Forecast & Price Target

LCTX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Lineage Cell Therapeutics is positioned for success with its COR1 program, utilizing its proprietary AlloSCOPE platform and leveraging ophthalmology and cell manufacturing expertise to achieve consistent, large-scale production of off-the-shelf allogeneic corneal endothelial cells. With COR1 addressing the current deficiencies of donor-derived CEnCs, Lineage can potentially capture a significant portion of the corneal transplant market, generating strong value for the stock. However, as with any biotech company, there are inherent risks in clinical/regulatory, partnership and financial, commercial, legal and intellectual property, and market share, which should be carefully monitored by investors.

Bears say

Lineage Cell Therapeutics is facing potential scalability and stability issues with its cell therapies due to its reliance on the AlloSCOPE platform and a single pluripotent cell line, and potential quality and safety concerns with its off-the-shelf strategy. While OpRegen shows initial promise, the company's reliance on partnerships and external validation, as well as its limited cash reserves, may hinder its potential for long-term success.

LCTX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Lineage Cell Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Lineage Cell Therapeutics Inc (LCTX) Forecast

Analysts have given LCTX a Strong Buy based on their latest research and market trends.

According to 4 analysts, LCTX has a Strong Buy consensus rating as of Aug 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Lineage Cell Therapeutics Inc (LCTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.